Recent developments in the management of recurrent Clostridioides difficile infection

被引：6
作者：
Mendo-Lopez, Rafael [1 ]
Villafuerte-Galvez, Javier [1 ]
White, Nicole [2 ]
Mahoney, Monica, V [3 ]
Kelly, Ciaran P. [1 ,4 ]
Alonso, Carolyn D. [2 ,4 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA
[3] Beth Israel Deaconess Med Ctr, Dept Pharm, Boston, MA 02215 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
来源：
ANAEROBE | 2020年 / 62卷
基金：
美国国家卫生研究院;
关键词：
Clostridioides difficile infection; Recurrence; Prophylaxis; Antibiotics; Bacteriotherapy; FECAL MICROBIOTA TRANSPLANTATION; DOUBLE-BLIND; VANCOMYCIN PROPHYLAXIS; ORAL VANCOMYCIN; PREVENTION; FIDAXOMICIN; GUIDELINES; EFFICACY; PHASE-2; ADULTS;
D O I：
10.1016/j.anaerobe.2019.102108
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Clostridioides (formerly Clostridium) difficile is responsible for a substantial burden of nosocomial infection. Recurrent C. difficile infection (rCDI) remains a concern due to its high morbidity, mortality, and cost. Despite the updated 2017 IDSA C. difficile treatment guidelines, there remains a lack of well-studied preventive control measures and treatment modalities for rCDI. There are ongoing efforts to develop novel therapies, such as new antibiotics with a lesser impact on gut microbiota and more targeted therapies, such as bacteriotherapy. This mini review highlights key rCDI management updates, preventive measures and ongoing research on novel treatment strategies including bacteriotherapy. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页数：8
相关论文
共 44 条
  • [1] [Anonymous], ZINPLAVATM BEZL PRES
  • [2] [Anonymous], SER 109 VERS PLAC PR
  • [3] [Anonymous], J PHARM PRACT
  • [4] [Anonymous], BIOL BLOOD MARROW TR
  • [5] [Anonymous], GASTROENTEROLOGY
  • [6] Vancomycin prophylaxis for Clostridium difficile infection among lung transplant recipients
    Bajrovic, Valida
    Budev, Marie
    McCurry, Kenneth R.
    Brizendine, Kyle D.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (08) : 874 - 876
  • [7] Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection
    Boix, Vicente
    Fedorak, Richard N.
    Mullane, Kathleen M.
    Pesant, Yves
    Stoutenburgh, Uschi
    Jin, Mandy
    Adedoyin, Adedayo
    Chesnel, Laurent
    Guris, Dalya
    Larson, Kajal B.
    Murata, Yoshihiko
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (01):
  • [8] Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections
    Carignan, Alex
    Poulin, Sebastien
    Martin, Philippe
    labbe, Annie-Claude
    Valiquette, Louis
    Al-Bachari, Hamed
    Montpetit, Louis-Philippe
    Pepin, Jacques
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (12) : 1834 - 1840
  • [9] Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses
    Caroff, Daniel A.
    Menchaca, John T.
    Zhang, Zilu
    Rhee, Chanu
    Calderwood, Michael S.
    Kubiak, David W.
    Yokoe, Deborah S.
    Klompas, Michael
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2019, 40 (06) : 662 - 667
  • [10] Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
    Cohen, Stuart H.
    Gerding, Dale N.
    Johnson, Stuart
    Kelly, Ciaran P.
    Loo, Vivian G.
    McDonald, L. Clifford
    Pepin, Jacques
    Wilcox, Mark H.
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (05) : 431 - 455
12345